Condition: SCN2A-DEE · Epilepsy · Sponsor: Praxis Precision Medicines
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
This description comes directly from the study's public registry record.
Head of Pharmacovigilance · 617-300-8460 · clinicaltrials@praxismedicines.com
Always discuss trial participation with your own doctor first.
| Le Bonheur Childrens Hospital | Memphis, Tennessee, United States | Completed |
| Hospital de Clinicas de Porto Alegre | Porto Alegre, Rio Grande do Sul, Brazil | Recruiting |
| Praxis Research Site | São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05737784